Skip to main content

Site notifications

(Approval lapsed 21 March 2018) BENZTROPINE OMEGA, benztropine mesylate2mg/2ml injection vial

Section 19A approved medicine
(Approval lapsed 21 March 2018) BENZTROPINE OMEGA, benztropine mesylate2mg/2ml injection vial
Section 19A approval holder
A. Menarini Australia Pty Ltd ABN 62 116 935 758
Phone
1800 644 542
Approved until
Status
Lapsed
Medicines in short supply/unavailable
COGENTIN benztropine mesilate 2mg/2mL injection ampoule - ARTG 10452
Indication(s)

Benztropine OMEGA is recommended for all etiologic groups of parkinsonism - arteriosclerotic, postencephalitic, idiophatic and drug-induced. It can be effective at any stage of the disease, even when a patient has become bedridden. Often it is helpful in patients who have become unresponsive to other agents. Therapy is directed toward control of disturbing symptoms to permit maximum integration of function and minimum discomfort. In non-drug-induced parkinsonism, partial control of symptoms is the usual therapeutic accomplishment. Benztropine OMEGA is a powerful anticholinergic agent, mainly effective in relieving tremor and rigidity.

Images
Picture of BENZTROPINE OMEGA benztropine mesylate 2mg/2ml injection vial - label
Picture of BENZTROPINE OMEGA benztropine mesylate 2mg/2ml injection vial -carton

Help us improve the Therapeutic Goods Administration site